FY2027 Earnings Forecast for ELAN Issued By Leerink Partnrs

Key Points

• Leerink Partners has increased its FY2027 earnings per share (EPS) estimate for Elanco Animal Health to $1.16, up from a previous forecast of $1.11, maintaining a "Strong-Buy" rating on the stock.
• Elanco reported a $0.26 EPS for the last quarter, exceeding the consensus estimate of $0.20, alongside a revenue of $1.24 billion which surpassed expectations of $1.19 billion.
• The consensus rating for Elanco Animal Health stock is a "Moderate Buy" with a target price averaging $17.33, reflecting positive sentiment among analysts despite a mixed variety of ratings from different firms.

Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) - Equities researchers at Leerink Partnrs increased their FY2027 earnings estimates for shares of Elanco Animal Health in a research note issued on Tuesday, September 2nd. Leerink Partnrs analyst D. Clark now anticipates that the company will earn $1.16 per share for the year, up from their prior forecast of $1.11. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Elanco Animal Health's current full-year earnings is $0.91 per share. Leerink Partnrs also issued estimates for Elanco Animal Health's FY2028 earnings at $1.34 EPS.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.20 by $0.06. The business had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. The company's revenue for the quarter was up 4.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.30 EPS. Elanco Animal Health has set its Q3 2025 guidance at 0.120-0.160 EPS. FY 2025 guidance at 0.850-0.91 EPS.

ELAN has been the subject of several other research reports. Zacks Research cut shares of Elanco Animal Health from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, August 20th. William Blair raised shares of Elanco Animal Health from a "market perform" rating to an "outperform" rating in a research report on Thursday, June 26th. Piper Sandler upped their price target on shares of Elanco Animal Health from $12.00 to $18.00 and gave the stock a "neutral" rating in a research report on Monday, August 11th. Wall Street Zen raised shares of Elanco Animal Health from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Finally, Stifel Nicolaus upped their price target on shares of Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $17.33.

Elanco Animal Health Trading Up 5.3%

ELAN stock traded up $0.93 during mid-day trading on Wednesday, reaching $18.40. The company had a trading volume of 6,921,928 shares, compared to its average volume of 10,348,335. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. The company has a market capitalization of $9.14 billion, a PE ratio of 21.39, a price-to-earnings-growth ratio of 3.42 and a beta of 1.62. The firm has a 50 day moving average of $15.95 and a 200 day moving average of $12.93. Elanco Animal Health has a 12 month low of $8.02 and a 12 month high of $18.87.

Institutional Trading of Elanco Animal Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allworth Financial LP lifted its holdings in shares of Elanco Animal Health by 791.7% during the 1st quarter. Allworth Financial LP now owns 2,354 shares of the company's stock valued at $25,000 after purchasing an additional 2,090 shares during the last quarter. CoreCap Advisors LLC purchased a new position in shares of Elanco Animal Health in the fourth quarter worth $29,000. NBC Securities Inc. purchased a new position in shares of Elanco Animal Health in the first quarter worth $40,000. Parallel Advisors LLC raised its holdings in shares of Elanco Animal Health by 92.2% in the first quarter. Parallel Advisors LLC now owns 3,860 shares of the company's stock worth $41,000 after buying an additional 1,852 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Elanco Animal Health by 65.9% in the first quarter. Versant Capital Management Inc now owns 4,382 shares of the company's stock worth $46,000 after buying an additional 1,740 shares during the last quarter. Hedge funds and other institutional investors own 97.48% of the company's stock.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.